InMode Ltd. (INMD)
| Market Cap | 1.99B |
| Revenue (ttm) | 177.92M |
| Net Income (ttm) | 57.95M |
| Shares Out | 36.70M |
| EPS (ttm) | 1.16 |
| PE Ratio | 52.37 |
| Forward PE | 28.49 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $60.70 |
| Previous Close | $60.87 |
| Change ($) | -0.17 |
| Change (%) | -0.28% |
| Day's Open | 61.07 |
| Day's Range | 60.27 - 62.20 |
| Day's Volume | 429,254 |
| 52-Week Range | 14.86 - 62.20 |
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
YOQNEAM, Israel, Jan. 6, 2021 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced it will present a corporate social responsibil...
InMode is an outperformer and leader in the growing medical aesthetic devices industry. Its products are made for a variety of purposes including liposuction, skin rejuvenation, cellulite trea...
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Is (INMD) Outperforming Other Medical Stocks This Year?
InMode (INMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Is (INMD) Outperforming Other Medical Stocks This Year?
InMode has seen a tough first and second quarter for obvious reasons, yet remained incredibly profitable. Net cash balances never put the viability of the company in doubt as valuations were f...
InMode Ltd. (INMD) CEO Moshe Mizrahy on Q3 2020 Results - Earnings Call Transcript
YOKNEAM, Israel, Nov. 12, 2020 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced consolidated financial resul...
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and...
Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.
YOKNEAM, Israel, Nov. 2, 2020 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that Mr. Moshe Mizrahy, Chairman and Chi...
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Perion (PERI), Live Oak (LOB), LexinFintech (LX) and InMode (INMD).
LAKE FOREST, Calif., Oct. 20, 2020 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, is pleased to introduce to the market th...
The cosmetic device maker's sales rebounded sharply in the third quarter.
These three health-related businesses are well positioned to provide market-beating gains.
InMode is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
The medical device maker announced a million-share repurchase program.
Growth stocks have been the market's biggest winners. Amid valuation concerns, these 10 stocks still have the potential for 100%-plus gains.
InMode went public in August, 2019, raising $70 million.
LAKE FOREST, Calif., Aug. 13, 2020 /PRNewswire/ -- InMode Ltd.
InMode Ltd. (INMD) CEO Moshe Mizrahy on Q2 2020 Results - Earnings Call Transcript
YOKNEAM, Israel, Aug. 5, 2020 /PRNewswire/ -- InMode Ltd.
YOKNEAM, Israel, Aug. 3, 2020 /PRNewswire/ -- InMode Ltd.
LAKE FOREST, Calif., July 27, 2020 /PRNewswire/ -- InMode Ltd.
InMode (INMD) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
The medical device maker's boosting its second-quarter guidance.
InMode (INMD) closed the most recent trading day at $28.07, moving +0.36% from the previous trading session.
InMode (INMD) closed at $31.15 in the latest trading session, marking a +1.1% move from the prior day.
In the latest trading session, InMode (INMD) closed at $31.15, marking a -1.61% move from the previous day.
InMode: A Look Into The Fundamentals Reveals A Clear Undervaluation
InMode Ltd. (INMD) CEO Moshe Mizrahy on Q1 2020 Results - Earnings Call Transcript
These small-cap stocks could rise by 1,000% or more in the 2020s, making them some of the best stocks to buy for the next 10 years.
InMode's (INMD) Q1 performance is likely to have been driven by developments in business segments amid coronavirus-led supply disruptions.
Some high-growth names in the beauty and fashion industries are trading at a discount.
Profitability analysis is one of the best ways to evaluate the prospects of a company.
Here are 5 ways to make the most of a difficult market.
The current economic slowdown led by rise in coronavirus cases calls for investing in defensive stocks.
InMode Ltd. (INMD) CEO Moshe Mizrahy on Q4 2019 Results - Earnings Call Transcript
Stocks Weather Apple News: RH Breaks Out, PAAS Nears Buy, InMode Dives
Stocks solid despite Apple: RH breaks out, Pan American Silver nears buy, InMode dives.
InMode (INMD) closed at $44.14 in the latest trading session, marking a -0.07% move from the prior day.
InMode's (INMD) Q4 performance is likely to have been driven by developments in business segments.
InMode (INMD) closed the most recent trading day at $42.81, moving -0.23% from the previous trading session.
InMode's BodyTite Procedure Is Less Attractive Than Investors Assume
Signet Jewelers, Microsoft, Tandem Diabetes, InMode and Taiwan Semi were our top stock trades for Friday -- and here's why.
Karuna Therapeutics, NextCure, and Cortexyme aren’t household names when it comes to investors looking at initial public offerings (IPOs), but they’ve been generating big-time returns for inve...
About INMD
InMode designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of pr... [Read more...]
| Industry Medical Devices | IPO Date Aug 8, 2019 |
| CEO Moshe Mizrahy | Employees 251 |
| Stock Exchange NASDAQ | Ticker Symbol INMD |
Financial Performance
In 2019, InMode's revenue was $156.36 million, an increase of 56.11% compared to the previous year's $100.16 million. Earnings were $61.15 million, an increase of 173.32%.
Analyst Forecasts
According to 3 analysts, the average rating for InMode stock is "Strong Buy." The 12-month stock price forecast is 63.67, which is an increase of 4.89% from the latest price.